The following is a summary of “Bio-artificial pancreas to treat type 1 diabetes: Perspectives from healthcare professionals ...
Lauren Torres had a baseball-sized tumor removed from her pancreas. Now she is back to everything else she loves to do — and ...
A recent paper published by Johns Hopkins researchers in the Department of Computer Science details the development and use ...
The discovery of a 'biomarker panel' could have a profound impact on the ability to identify patients at risk of developing ...
Zacks.com on MSN23h
Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?Exelixis, Inc. EXEL reported better-than-expected fourth-quarter results. EXEL recorded earnings of 55 cents per share, which ...
Rezolute advances therapies for hypoglycemia with RZ358 and RZ402, showing efficacy in trials. Read why RZLT stock is a ...
According to Johns Hopkins Pathology, pancreatic cancer is more common in African Americans and often diagnosed in advanced ...
A new blood test could help doctors detect pancreatic cancer earlier, potentially improving survival rates for one of the ...
Zacks.com on MSN6d
EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in FocusExelixis, Inc. EXEL reported better-than-expected fourth-quarter results. EXEL recorded earnings of 55 cents per share, which beat the Zacks Consensus Estimate of 51 cents. The company registered ...
Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback